关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
" M8 l, R7 q5 G1 m* P    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
- T. ^0 p7 w; W* n. {3 @2 D# M
作者：来自澳大利亚
2 L' w3 v& r8 v7 P* {" v来源：Haematologica. 2011.8.9.
, s) R  h2 ~9 L: M, @8 J3 LDear Group,

* g5 p5 d7 l" USome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
6 j+ b3 U+ ^/ qtherapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
remain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.
& z; _1 J+ d  Q3 ]. H
The remarkable news about Sprycel cessation is that all 3 patients had failed
. ^& N3 l5 P3 qGleevec and Sprycel was their second TKI so they had resistant disease. This is
7 d2 x0 C% J, f7 A! ?  Idifferent from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.

. _0 ^1 m" G; m! M. C1 j6 {3 |Hopefully, the doctors will report on a larger study and long-term to see if the
; ~1 _7 w( B4 Nresponse off Sprycel is sustained.
. h  s, |1 F. r1 [/ I  a  t/ M  @
Best Wishes,
Anjana
4 b0 Z3 S% z$ o  S( |; {* T. |
0 Z2 G4 C0 G; k

/ m6 G0 M# u1 lHaematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
( e' k+ t& O  r6 {8 z2 V) WAdelaide, Australia;
. o; C8 E: \% u0 j
Abstract
, Q4 p! n" Y3 k! XPatients with chronic myeloid leukemia, treated with imatinib, who have a
1 l# f8 w" w4 f7 b/ G; Cdurable complete molecular response might remain in CMR after stopping
treatment. Previous reports of patients stopping treatment in complete molecular
5 W9 N! n& H1 O/ m4 E- Bresponse have included only patients with a good response to imatinib. We
( D/ E- Q- e/ X2 v/ J4 w  mdescribe three patients with stable complete molecular response on dasatinib
treatment following imatinib failure. Two of the three patients remain in
; {4 |& S: P3 ]complete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
& I$ z$ D! x7 ~9 }# K3 qshow that the leukemic clone remains detectable, as we have previously shown in
: L+ |2 y. F. Y- D+ G9 Gimatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
! y( g% o: ~' x% i: L/ Y) ]7 @who relapsed and in one patient in remission. Our results suggest that the
# m8 U; c& p$ scharacteristics of complete molecular response on dasatinib treatment may be
4 Y) x% ]1 {: ~) C! Osimilar to that achieved with imatinib, at least in patients with adverse
4 u: F4 u3 e/ y! H( jdisease features.
2 H/ v6 H! p- |8 G- f7 `1 }$ g

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。

3 u* }/ W6 N( s作者：来自法国STIM试验
6 Y" }4 b- H5 U# q8 Y8 [% Y来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事